Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a crossover trial of BCX4161 prophylaxis in hereditary angioedema
2013-002319-82Phase 2Completed
- Sponsor
- BioCryst Pharmaceuticals, Inc.
- Start
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of avoralstat in hereditary angioedema (HAE) (2 arms), sponsored by BioCryst Pharmaceuticals, Inc. Primary endpoint: Number of acute attacks. Started Jul 2013; status: completed.
02
Drugs
avoralstat
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on 2013-002319-82.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002319-82.